Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964807 · ClinicalTrials.gov registry record · NA
Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 81
- Enrollment target
NCT01964807 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 81 participants.
The verdict
NCT01964807, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 81 participants
- Enrollment target
Study Summary
The overarching goal of this project is to develop a panel of cardiovascular risk biomarkers that can detect differences in the cardiovascular safety of various tobacco products, whether conventional, new or emerging, in order to help the FDA with the task of regulating them. This will be achieved through 4 aims: Aim 1: Determine the relative contributions of nicotine and combustion products to the cardiovascular risk of active cigarette smoking. Aim 2: Determine which cardiovascular risk biomarkers are affected by exposure to secondhand smoke. Aim 3: Determine the cardiovascular risk of smokeless tobacco use. Aim 4: Determine the cardiovascular risk of electronic cigarettes and the respective contributions of nicotine and electronic cigarette vapor.
Interventions
- OTHER Cigarette, NIDA test type with 16.6 mg nicotine
- OTHER Cigarette, NIDA test type with <0.45 mg nicotine
- OTHER Electronic cigarette with 18 mg/ml nicotine
- OTHER Electronic Cigarette with no nicotine
- OTHER Moist snuff
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2013-11-03 |
| Est. Completion | 2021-05-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01964807
The ClinicalTrials.gov registry entry for NCT01964807 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cigarette, NIDA test type with 16.6 mg nicotine is the first listed.
NCT01964807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01964807 about?
NCT01964807 is a clinical study titled "Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products". The overarching goal of this project is to develop a panel of cardiovascular risk biomarkers that can detect differences in the cardiovascular safety of various tobacco products, whether conventional, new or emerging, in order to help the FDA with the task of regulating them. This will be achieved t...
What is the current status of trial NCT01964807?
This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2013-11-03. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT01964807?
The interventions under investigation include: Cigarette, NIDA test type with 16.6 mg nicotine (OTHER), Cigarette, NIDA test type with <0.45 mg nicotine (OTHER), Electronic cigarette with 18 mg/ml nicotine (OTHER), Electronic Cigarette with no nicotine (OTHER), Moist snuff (OTHER).
Who is sponsoring clinical trial NCT01964807?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.